Positive results for Alkermes’ Phase III study spell good news for major depressive disorder space
GlobalData anticipates ALKS-5461 will enter the US market in early 2018.
Positive topline results have been announced by Alkermes for its Phase III study of ALKS-5461 as an adjunctive therapy for major depressive disorder (MDD), according to research and consulting firm GlobalData.
As explored in GlobalData’s most recent MDD report, ALKS-5461 is one of six late-stage pipeline products showing promise with regards to improving efficacy and safety in the treatment of patients with the disorder. In October 2013, ALKS-5461 was granted fast track designation by the FDA for the adjunctive treatment of MDD in patients with an inadequate response to standard antidepressant therapies.
Christos Michaelides, GlobalData's Analyst covering Neurology and Ophthalmology, explains: “This status will both facilitate and expedite the FDA developmental and regulatory review process for ALKS-5461, which GlobalData anticipates will enter the US market in early 2018.
“Current treatment options for MDD tend to rely on selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors; however, these antidepressants are not ideal, as approximately one third of patients do not demonstrate any remission of symptoms. Those who do not respond to two or more antidepressant therapies are referred to as ‘treatment-resistant,’ and ALKS-5461 is aimed towards providing a therapy for these patients.”
Although ALKS-5461 has a novel mechanism of action that is expected to provide benefit to MDD patients, it is expected that patient uptake may be negatively impacted by the outcomes of previous Phase III trials, which have been less positive. Furthermore, the drug is likely to find itself facing competition from other emerging pipeline therapies that have demonstrated more robust efficacy in treatment-resistant patients, such as Janssen’s esketamine or Allergan’s rapastinel.
Michaelides continues: “The risk of dependency due to ALKS-5461’s action through the opioid system is also a concern, which may compromise uptake. However, such concerns may already be mitigated through the demonstrated supportive clinical data showing that there was no difference in abuse potential between ALKS-5461 and placebo.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance